Serostatus May Modify RA Activity–CV Link
Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.
By
Andrea Surnit
July 15, 2026
Clinical Scorecard: Serostatus May Modify RA Activity–CV Link
At a Glance
Category Detail
Condition Rheumatoid Arthritis Key Mechanisms Association between rheumatoid arthritis disease activity and major adverse cardiovascular events, modified by serostatus. Target Population Patients with prevalent rheumatoid arthritis and no established or suspected cardiovascular disease. Care Setting Academic referral centers
Key Highlights
Higher rheumatoid arthritis disease activity linked to increased risk of cardiovascular events. Each 1-unit increase in DAS28-CRP associated with an 18% higher hazard of cardiovascular events. Combined serostatus of RF and ACPA may influence cardiovascular risk assessment. 184 patients experienced a first major adverse cardiovascular event during follow-up. Caution advised against interpreting low disease activity as low cardiovascular risk. Guideline-Based Recommendations
Diagnosis
Assess disease activity using DAS28-CRP. Management
Consider serostatus when evaluating cardiovascular risk in rheumatoid arthritis patients. Monitoring & Follow-up
Monitor disease activity and cardiovascular risk factors at enrollment. Risks
Patients with low disease activity should not be assumed to have low cardiovascular risk. Patient & Prescribing Data
Patients with rheumatoid arthritis enrolled in the ATACC-RA consortium.
Corticosteroid use and traditional cardiovascular risk factors should be considered in management.
Clinical Best Practices
Evaluate combined serostatus for cardiovascular risk assessment. Use imaging-based risk reclassification in selected serologic groups. Related Resources & Content
